Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model

Cancer Letters

Volumn 238, Issue 1, 2006, Pages 104-110

  Saw, Constance Lay Lay ^a   Heng, Paul Wan Sia ^a   Chin, William Wei Lim ^b   Soo, Khee Chee ^c   Olivo, Malini ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chick chorioalllantoic membrane; Formulation; Hypericin; N Methyl pyrrolidone; Photodynamic therapy; Vasculature

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ALBUMIN; HYPERICIN; N METHYLPYRROLIDONE; PENETRATION ENHANCING AGENT; PHARMASOLVE; PLASMA PROTEIN; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BLOOD VESSEL INJURY; CHICK; CHORIOALLANTOIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMBRYO; LIGHT IRRADIANCE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; SOLID TUMOR; SOLUBILIZATION;

ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DRUG CARRIERS; LIGHT; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PYRROLIDINONES;

EID: 33744929619     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.026     Document Type: Article

References (33)

1. Agostinis P., Vantieghem A., Merlevede W., and de Witte P.A. Hypericin in cancer treatment: more light on the way. Int. J. Biochem. Cell. Biol. 34 (2002) 221-241
2. Kubin A., Wierrani F., Burner U., Alth G., and Grunberger W. Hypericin-the facts about a controversial agent. Curr. Pharm. Des. 11 (2005) 233-253
3. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1 (2001) 385-401
4. Miskovsky P., Sureau F., Chinsky L., and Turpin P.Y. Subcellular distribution of hypericin in human cancer cells. Photochem. Photobiol. 62 (1995) 546-549
5. Kamuhabwa A.R., Augustijns P., and De Witte P.A. In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. Int. J. Pharm. 188 (1999) 81-86
6. Chen B., and de Witte P.A. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 150 (2000) 111-117
7. Andreoni A., Colasanti A., Colasanti P., Mastrocinque M., Riccio P., and Roberti G. Laser photosensitization of cells by hypericin. Photochem. Photobiol. 59 (1994) 529-533
8. D'Hallewin M.A., Kamuhabwa A.R., Roskams T., De Witte P.A., and Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. Br. J. Urol. Int. 89 (2002) 760-763
9. Das K., Smirnov A.V., Wen J., Miskovsky P., and Petrich J.W. Photophysics of hypericin and hypocrellin A in complex with subcellular components: interactions with human serum albumin. Photochem. Photobiol. 69 (1999) 633-645
10. Huygens A., Kamuhabwa A.R., and de Witte P.A.M. Stability of different formulations and ion pairs of hypericin. Eur. J. Pharm. Biopharm. 59 (2005) 461-468
11. Huygens A., Kamuhabwa A.R., van Cleynenbreugel B., van Poppel H., Roskams T., and de Witte P.A. In vivo accumulation of different hypericin ion pairs in the urothelium of the rat bladder. Br. J. Urol. Int. 95 (2005) 436-441
12. Vargas A., Pegaz B., Debefve E., Konan-Kouakou Y., Lange N., Ballini J.P., et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int. J. Pharm. 286 (2004) 131-145
13. Konan Y.N., Gurny R., and Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B 66 (2002) 89-106
14. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (2001) 1590-1598
15. Derycke A.S.L., and de Witte P.A.M. Liposomes for photodynamic therapy. Adv. Drug Deliv. Rev. 56 (2004) 17-30
16. Chin W., Lau W., Lay S.L., Wei K.K., and Olivo M. Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones. Int. J. Oncol. 25 (2004) 887-891
17. Saw C.L., Olivo M., Chin W.W., Soo K.C., and Heng P.W. Transport of hypericin across chick chorioallantoic membrane and photodynamic therapy vasculature assessment. Biol. Pharm. Bull. 28 (2005) 1054-1060
18. Suwanpidokkul N., Thongnopnua P., and Umprayn K. Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS Pharm. Sci. Tech. 5 (2004) e48
19. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 61 (2003) 25-31
20. Richardson M., and Singh G. Observations on the use of the avian chorioallantoic membrane (CAM) model in investigations into angiogenesis. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3 (2003) 155-185
21. Hammer-Wilson M.J., Cao D., Kimel S., and Berns M.W. Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for photosensitizers administered intraperitoneally (IP) into the chick embryo. Photochem. Photobiol. Sci. 1 (2002) 721-728
22. Tan I.B., Oppelaar H., Ruevekamp M.C., Veenhuizen R.B., Timmers A., and Stewart F.A. The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors. Head Neck 21 (1999) 434-441
23. Chen B., Roskams T., and de Witte P.A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem. Photobiol. 76 (2002) 509-513
24. Hammer-Wilson M.J., Akian L., Espinoza J., Kimel S., and Berns M.W. Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers. J. Photochem. Photobiol. B 53 (1999) 44-52
25. Koren H., Schenk G.M., Jindra R.H., Alth G., Ebermann R., Kubin A., et al. Hypericin in phototherapy. J. Photochem. Photobiol. B 36 (1996) 113-119
26. Romanoff A.L., and Romanoff A.J. Biochemistry of the Avian Embryo: A Quantitative Analysis of Prenatal Development (1967), Interscience Publishers, New York pp. 341
27. Leng T., Miller J.M., Bilbao K.V., Palanker D.V., Huie P., and Blumenkranz M.S. The chick chorioallantoic membrane as a model tissue for surgical retinal research and simulation. Retina 24 (2004) 427-434
28. Maragoudakis M.E., Panoutsacopoulou M., and Sarmonika M. Rate of basement membrane biosynthesis as an index to angiogenesis. Tissue Cell. 20 (1988) 531-539
29. Ribatti D., Nico B., Vacca A., Roncali L., Burri P.H., and Djonov V. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat. Rec. 264 (2001) 317-324
30. Leighton J., Nassauer J., and Tchao R. The chick embryo in toxicology: an alternative to the rabbit eye. Food Chem. Toxicol. 23 (1985) 293-298
31. Lange N., Ballini J.P., Wagnieres G., and van den Bergh H. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest. Ophthalmol. Vis. Sci. 42 (2001) 38-46
32. Kunzi-Rapp K., Ruck A., and Kaufmann R. Characterization of the chick chorioallantoic membrane model as a short-term in vivo system for human skin. Arch. Dermatol. Res. 291 (1999) 290-295
33. Kunzi-Rapp K., Genze F., Kufer R., Reich E., Hautmann R.E., and Gschwend J.E. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J. Urol. 166 (2001) 1502-1507